Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19004040 | 0.85 | MAPT (1.00) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL22379752 | 0.82 | LMNA (0.54) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL27811794 | 0.81 | HDAC1 (0.66) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL29366285 | 0.81 | HDAC1 (0.66) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL93423 | 0.81 | HDAC1 (0.66) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL2997751 | 0.80 | MAOA (0.54) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL5069965 | 0.79 | MAPT (0.69) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL78196 | 0.79 | GAA (0.56) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL29557032 | 0.79 | GAA (0.56) | LMNAMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL7915213 | 0.79 | GAA (0.56) | LMNAMAPTHTTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2021-07-29 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-10959979-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2020-08-27 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-10646465-B2 | Small molecules against cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2020-05-12 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | ALONBIO LTD. (IL) | 2019-08-08 | — | — | US | disclosed |
| WO-2017103931-A1 | SMALL MOLECULES AGAINST CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959979-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | LMNA 4286/4885MAPT 4157/4885HTT 4017/4885 |
| US-20210228535-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | LMNA 4286/4885MAPT 4157/4885HTT 4017/4885 |
| US-10646465-B2 | Small molecules against cancer | CCL2, CXCR2, CCL5 | LMNA 4286/4885MAPT 4157/4885HTT 4017/4885 |
| US-20200268709-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | LMNA 4286/4885MAPT 4157/4885HTT 4017/4885 |
| US-20190240188-A1 | SMALL MOLECULES AGAINST CANCER | CCL2, CXCR2, CCL5 | LMNA 4286/4885MAPT 4157/4885HTT 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.